{"id":389900,"date":"2022-01-31T00:00:00","date_gmt":"2022-01-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2021-biopharma-schizophrenia-disease-landscape-forecast-g7-2021\/"},"modified":"2026-05-03T11:20:33","modified_gmt":"2026-05-03T11:20:33","slug":"dlsfcg0006-2021-biopharma-schizophrenia-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2021-biopharma-schizophrenia-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Schizophrenia | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for the late-phase and recently approved therapies not specifically targeting schizophrenia subpopulations with high unmet need\u2014including new oral atypical antipsychotics (e.g., Alkermes\u2019s Lybalvi), new LAIs (e.g., Janssen\u2019s paliperidone six-month depot, Teva\u2019s TV-46000), and other agents with novel mechanisms of action (e.g., Sunovion \/ Sumitomo Dainippon Pharma\u2019s ulotaront [SEP-363856], Karuna\u2019s KarXT). Although the potential of therapies in development to treat the negative symptoms of schizophrenia or the cognitive impairment associated with schizophrenia (CIAS) remains to be seen in late-phase studies, some agents had promising results in mid-phase clinical studies and could earn blockbuster sales, such as Acadia Pharmaceuticals\u2019 pimavanserin and Boehringer Ingelheim\u2019s BI 425809.<\/p>\n<p><strong>Questions <\/strong><strong>Answered<\/strong><\/p>\n<ul>\n<li>What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?<\/li>\n<li>What percentage of diagnosed lifetime prevalent schizophrenia patients receive drug treatment? How large are the schizophrenia subpopulations with negative symptoms or cognitive impairment?<\/li>\n<li>What are the greatest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs?<\/li>\n<li>How will novel emerging therapies be positioned in the schizophrenia treatment algorithm?<\/li>\n<\/ul>\n<p><strong>Product Description: <\/strong><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement:<\/strong> <em>Disease Landscape &#038; Forecast<\/em> will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p><strong>Geographies:<\/strong> United States, EU5, Japan.<\/p>\n<p><strong>Primary research: <\/strong>28 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country.<\/p>\n<p><strong>Forecast:<\/strong> Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2030, segmented by brands \/ generics.<\/p>\n<p><strong>Emerging therapies: <\/strong>Phase III \/ PR: 10 drugs. Coverage of select Phase II and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-389900","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-schizophrenia","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389900\/revisions"}],"predecessor-version":[{"id":576277,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389900\/revisions\/576277"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}